CNSP · CNS Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| John M. Climaco Chief Executive Officer | ▲ Buy | Open Market | 215,676 Shares held | 2/1/2024 | View profile |
| Waldemar Priebe 10% Owner | ▼ Sell | Open Market | 156,807 Shares held | 3/28/2023 | View profile |
| Christopher Downs Chief Financial Officer | ▲ Buy | Open Market | 103,438 Shares held | 2/1/2024 | View profile |
| Jerzy Gumulka Director | ▲ Buy | Open Market | 43,006 Shares held | 2/1/2024 | View profile |
| Carl Anthony Evans Director | ▲ Buy | Open Market | 33,458 Shares held | 2/1/2024 | View profile |
| Jeffry R. Keyes Chief Financial Officer | ▲ Buy | Grant | 11,100 Shares held | 3/7/2022 | View profile |
| Faith L. Charles Director | ▲ Buy | Open Market | 7,100 Shares held | 5/18/2026 | View profile |
| Levin Rami CEO and President | ▲ Buy | Option Exercise | 4,750 Shares held | 8/14/2026 | View profile |
| Fisher Michal Director | ▲ Buy | Open Market | 2,000 Shares held | 5/18/2026 | View profile |
Transaction History
| Levin Rami | ▲ Buy | Option Exercise | 4,750 | $0 | 8/14/2026 |
| Faith L. Charles | ▲ Buy | Open Market | 7,100 | $34K | 5/18/2026 |
| Fisher Michal | ▲ Buy | Open Market | 2,000 | $10K | 5/18/2026 |
| Jerzy Gumulka | ▲ Buy | Open Market | 33,333 | $10K | 2/1/2024 |
| Carl Anthony Evans | ▲ Buy | Open Market | 33,333 | $10K | 2/1/2024 |
| Christopher Downs | ▲ Buy | Open Market | 66,666 | $20K | 2/1/2024 |
| John M. Climaco | ▲ Buy | Open Market | 166,666 | $50K | 2/1/2024 |
| Christopher Downs | ▲ Buy | Open Market | 27,000 | $34K | 8/22/2023 |
| John M. Climaco | ▲ Buy | Open Market | 2,750 | $5K | 8/16/2023 |
| John M. Climaco | ▲ Buy | Option Exercise | 1,250 | — | 4/28/2023 |
| Christopher Downs | ▲ Buy | Option Exercise | 521 | — | 4/28/2023 |
| Jerzy Gumulka | ▲ Buy | Open Market | 2,500 | $4K | 4/19/2023 |
| Christopher Downs | ▲ Buy | Open Market | 3,100 | $10K | 4/17/2023 |
| John M. Climaco | ▲ Buy | Open Market | 15,000 | $10K | 4/12/2023 |
| Jerzy Gumulka | ▲ Buy | Open Market | 7,173 | $5K | 4/10/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 10,000 | $10K | 3/28/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $5K | 3/27/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $5K | 3/24/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 10,000 | $11K | 3/23/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $5K | 3/22/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $6K | 3/21/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $5K | 3/20/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $6K | 3/17/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $6K | 3/16/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $6K | 3/15/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $7K | 3/14/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $7K | 3/13/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,000 | $6K | 3/10/2023 |
| Waldemar Priebe | ▼ Sell | Open Market | 2,798 | $7K | 12/9/2022 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,500 | $13K | 12/8/2022 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,500 | $14K | 12/7/2022 |
| Waldemar Priebe | ▼ Sell | Open Market | 5,500 | $14K | 12/6/2022 |
| Christopher Downs | ▲ Buy | Grant | 33,000 | $10K | 3/11/2022 |
| Carl Anthony Evans | ▲ Buy | Grant | 3,750 | $1K | 3/8/2022 |
| Jeffry R. Keyes | ▲ Buy | Grant | 11,100 | $3K | 3/7/2022 |
| John M. Climaco | ▲ Buy | Grant | 35,000 | $10K | 3/7/2022 |
| Christopher Downs | ▲ Buy | Open Market | 5,000 | $5K | 12/6/2021 |
| Christopher Downs | ▲ Buy | Open Market | 4,500 | $5K | 11/19/2021 |
| John M. Climaco | ▲ Buy | Grant | 5,000 | $6K | 11/16/2021 |
| Waldemar Priebe | ▼ Sell | Other | 1,495,867 | — | 5/5/2020 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
CNS Pharmaceuticals Holds Shareholder/Analyst Call
On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.
CNS Pharmaceuticals Holds Shareholder/Analyst Call. On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.